GlassScriptPhysician profile
William T Denton
NPI 1578506044
$4,236.57
in general payments reported to CMS, 2019-2025
27 companies · $56.17 in 2025
The $56.17 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $516 · 2021: $1,073 · 2022: $248 · 2023: $278 · 2024: $163 · 2025: $56.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $983.13 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $887.77 | 2019-2024 | Tremfya, Stelara |
| Abbvie INC. | $718.02 | 2019-2023 | Rinvoq, Skyrizi |
| Pfizer INC. | $352.75 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $149.73 | 2019-2021 | |
| Allergan, INC. | $131.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.18 | 2021 | |
| Ucb, INC. | $95.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $66.48 | 2022-2023 | Dupixent |
| Celgene Corporation | $56.91 | 2021 | |
| Stryker Corporation | $56.17 | 2025 | Flowtriever |
| Ironwood Pharmaceuticals, INC | $52.75 | 2019-2023 | Linzess |
| Shire North American Group INC | $40.04 | 2019 | |
| Medtronic USA, INC. | $30.59 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $25.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $25.14 | 2019-2020 | |
| Evoke Pharma, INC. | $24.96 | 2023 | Gimoti |
| Genzyme Corporation | $22.84 | 2023 | |
| Ardelyx, INC. | $22.53 | 2023 | Ibsrela |
| Redhill Biopharma INC. | $17.39 | 2020 | |
| Amgen INC. | $16.62 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $14.44 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.85 | 2019 | |
| Qol Medical, LLC | $12.72 | 2019 | |
| Gilead Sciences, INC. | $12.52 | 2019 | |
| Medtronic, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Denton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.